Quality of life with durvalumab in stage III non-small-cell lung cancer

Lancet Oncol. 2019 Dec;20(12):1619-1620. doi: 10.1016/S1470-2045(19)30643-6. Epub 2019 Oct 7.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Carcinoma, Non-Small-Cell Lung*
  • Chemoradiotherapy
  • Humans
  • Lung Neoplasms*
  • Patient Reported Outcome Measures
  • Quality of Life

Substances

  • Antibodies, Monoclonal
  • durvalumab